Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307 is registered in ClinicalTrials.gov with Global Alzheimer's Platform Foundation as lead sponsor.

NCT NCT05364307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)
Lead sponsor
Global Alzheimer's Platform Foundation
Phase
Observational
Overall status
Completed
Start date
June 13, 2022
Completion date
January 31, 2025
Enrollment
1,555 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, memory disorders, memory impairment, memory loss, mild cognitive impairment